ReNeuron
From Wikipedia, the free encyclopedia
| Company type | Public company |
|---|---|
| LSE: RENE | |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
| Website | reneuron.com |
ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration.[1] Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration.[2] They were also testing the use of fetal stem cells on stroke patients.[3]
